Posts Tagged: Stem cell agency
News
One year ago this month, five-year-old Sheersha Sulack asked Santa to bring her a suitcase to carry her toys with her for an arduous treatment that her parents hoped would save her from a rare, life-threatening affliction known as the bubble baby disease. Development of the therapy is part of a unique effort that has put the Golden State at the forefront of the development of gene and cell therapies.
News
The chief executive officer of California’s $12 billion stem cell and gene therapy program, Maria T. Millan, resigned abruptly this week, leaving what is the largest such state research effort in the nation without even an interim leader. Millan’s departure comes as the agency faces major challenges. They include expansion of an embryonic effort to assure the affordability of CIRM’s potential treatments that could cost millions of dollars. Some of the directors are also behind a move to sharpen its focus and reset its priorities.
News
Directors of the $12 billion California stem cell agency will face a fundamental question next week that could determine whether its efforts to produce revolutionary treatments for afflictions ranging from heart disease to cancer will live or die.
News
Nine California research organizations will vie behind closed doors this week as the state’s stem cell agency scores their bids to kick off what would be a first-in-the-nation, $80 million manufacturing network to speed the development of revolutionary medical therapies.
News
It was a $137 million day for the Golden State’s stem cell agency — no small event even for an enterprise that is backed by billions. The scientific scope covered by the $137 million was impressive. It ranged from bolstering the vaunted Alpha Clinic Network initiated around the state by the California Institute for Regenerative Medicine (CIRM), as the agency is legally known, to raising the number of CIRM’s clinical trials to 83.
News
In a first in its 18-year history, the California stem cell agency has begun posting on its website a list of its governing board members who have conflicts of interest as they award hundreds of millions of dollars. The most recent example comes next Tuesday in a $48 million round that will benefit at least 16 public and private colleges in the Golden State and up to 400 students at a cost of $58,220 each.
News
The “bubble babies” saga and a California-financed cure for their life-threatening affliction has hit another snag, more than two years after a British company abandoned the effort. It is a story that involves more than $40 million from California’s stem cell agency, federal regulators, the University of California, the agonizingly slow pace of science and 20 children who have been denied care — not to mention a company called Orchard Therapeutics PLC.
News
California’s $12 billion stem cell agency needs to do better in several critical areas, ranging from planning for the replacement of its current chair to handling information that is key to its operations as well as the tracking of potential sources of royalties. That’s according to that latest performance audit of the 17-year-old agency.
News
A London-based biotech firm has given up its life-saving treatment for the bubble baby disease and turned it over to California’s $12 billion stem cell agency and UCLA, where it was developed with tens of millions of taxpayer dollars.
News
Larry Goldstein, a well-known stem cell researcher at the University of California, San Diego who has received nearly $22 million in awards from the California stem cell agency, today was named to its governing board. It was the first time in the history of the 16-year-old agency that a scientist who has received agency awards has been appointed to the board.
Sheersha Sulack and Donald Kohn (with glasses) earlier this year on the day she received a cell treatment.
